[{"id":"63139aa8-19bf-4602-a810-5c7110a10962","acronym":"","url":"https://clinicaltrials.gov/study/NCT04423185","created_at":"2021-01-18T21:18:39.174Z","updated_at":"2025-02-25T15:26:22.079Z","phase":"Phase 2","brief_title":"PLATFORM Study of Precision Medicine for Rare Tumors","source_id_and_acronym":"NCT04423185","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification","tags":["EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 770","initiation":"Initiation: 08/15/2020","start_date":" 08/15/2020","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-11"},{"id":"2e5ccca8-120c-4e72-b9c4-3d96418121c2","acronym":"NCI-2018-01218","url":"https://clinicaltrials.gov/study/NCT03065387","created_at":"2021-01-18T15:06:02.917Z","updated_at":"2025-02-25T15:25:34.097Z","phase":"Phase 1","brief_title":"Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation","source_id_and_acronym":"NCT03065387 - NCI-2018-01218","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • KRAS • ERBB3 • ERBB4","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • HER-2 amplification • EGFR amplification","tags":["HER-2 • KRAS • ERBB3 • ERBB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • HER-2 amplification • EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Ibrance (palbociclib) • everolimus • Nerlynx (neratinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 93","initiation":"Initiation: 10/31/2017","start_date":" 10/31/2017","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-02-10"},{"id":"55ef4527-2517-4df0-b7b1-87bc17764e8d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06075615","created_at":"2023-10-10T14:12:08.091Z","updated_at":"2025-02-25T16:33:44.056Z","phase":"","brief_title":"A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.","source_id_and_acronym":"NCT06075615","lead_sponsor":"Pfizer","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vizimpro (dacomitinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/30/2024","start_date":" 09/30/2024","primary_txt":" Primary completion: 09/07/2026","primary_completion_date":" 09/07/2026","study_txt":" Completion: 09/07/2026","study_completion_date":" 09/07/2026","last_update_posted":"2025-02-07"},{"id":"ed58f223-816b-4b86-8902-43d45b3105ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT04155541","created_at":"2021-01-18T20:16:31.922Z","updated_at":"2025-02-25T16:37:36.723Z","phase":"","brief_title":"Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)","source_id_and_acronym":"NCT04155541","lead_sponsor":"Pfizer","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vizimpro (dacomitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/24/2020","start_date":" 01/24/2020","primary_txt":" Primary completion: 08/25/2026","primary_completion_date":" 08/25/2026","study_txt":" Completion: 08/25/2026","study_completion_date":" 08/25/2026","last_update_posted":"2025-02-06"},{"id":"1d4264b1-4ecd-48a1-88aa-d47b1b9d9638","acronym":"","url":"https://clinicaltrials.gov/study/NCT03810807","created_at":"2021-01-18T18:49:46.476Z","updated_at":"2025-02-25T16:52:25.068Z","phase":"Phase 1","brief_title":"Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer","source_id_and_acronym":"NCT03810807","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Vizimpro (dacomitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 01/17/2019","start_date":" 01/17/2019","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-04"},{"id":"2585cfc6-1e39-425e-88e3-8b16e0513970","acronym":"","url":"https://clinicaltrials.gov/study/NCT04721106","created_at":"2021-01-22T12:54:25.860Z","updated_at":"2025-02-25T16:53:29.813Z","phase":"","brief_title":"Korea Post Marketing Surveillance (PMS) Study of Vizimpro","source_id_and_acronym":"NCT04721106","lead_sponsor":"Pfizer","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vizimpro (dacomitinib)"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 187","initiation":"Initiation: 03/07/2021","start_date":" 03/07/2021","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/30/2026","study_completion_date":" 03/30/2026","last_update_posted":"2025-02-04"},{"id":"a526062e-0dec-4bcb-ad38-667bba3155fb","acronym":"ARIA","url":"https://clinicaltrials.gov/study/NCT04609319","created_at":"2021-01-19T20:32:06.457Z","updated_at":"2024-07-02T16:35:06.937Z","phase":"","brief_title":"Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review","source_id_and_acronym":"NCT04609319 - ARIA","lead_sponsor":"Pfizer","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vizimpro (dacomitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 01/23/2021","start_date":" 01/23/2021","primary_txt":" Primary completion: 06/04/2024","primary_completion_date":" 06/04/2024","study_txt":" Completion: 10/08/2024","study_completion_date":" 10/08/2024","last_update_posted":"2024-04-30"},{"id":"d8b2ddac-f3fc-4cd6-b2ee-039837b929f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04511533","created_at":"2021-01-18T21:37:31.070Z","updated_at":"2024-07-02T16:35:11.244Z","phase":"Phase 4","brief_title":"Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations","source_id_and_acronym":"NCT04511533","lead_sponsor":"Pfizer","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vizimpro (dacomitinib)"],"overall_status":"Completed","enrollment":" Enrollment 101","initiation":"Initiation: 08/27/2020","start_date":" 08/27/2020","primary_txt":" Primary completion: 10/15/2022","primary_completion_date":" 10/15/2022","study_txt":" Completion: 11/08/2022","study_completion_date":" 11/08/2022","last_update_posted":"2024-04-05"},{"id":"f35e6550-13c5-46f1-8099-379452a3a89e","acronym":"ARCHER 1050","url":"https://clinicaltrials.gov/study/NCT01774721","created_at":"2021-01-17T17:11:15.852Z","updated_at":"2024-07-02T16:35:29.318Z","phase":"Phase 3","brief_title":"ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.","source_id_and_acronym":"NCT01774721 - ARCHER 1050","lead_sponsor":"Pfizer","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gefitinib • Vizimpro (dacomitinib)"],"overall_status":"Completed","enrollment":" Enrollment 452","initiation":"Initiation: 05/09/2013","start_date":" 05/09/2013","primary_txt":" Primary completion: 07/29/2016","primary_completion_date":" 07/29/2016","study_txt":" Completion: 01/27/2022","study_completion_date":" 01/27/2022","last_update_posted":"2023-11-14"},{"id":"4820f7c8-a813-4272-a505-df6ea07f61f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01000025","created_at":"2021-01-18T03:54:34.967Z","updated_at":"2024-07-02T16:35:39.394Z","phase":"Phase 3","brief_title":"PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer","source_id_and_acronym":"NCT01000025","lead_sponsor":"NCIC Clinical Trials Group","biomarkers":" EGFR • KRAS","pipe":" | ","alterations":" EGFR mutation • KRAS wild-type","tags":["EGFR • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • KRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Vizimpro (dacomitinib)"],"overall_status":"Completed","enrollment":" Enrollment 720","initiation":"Initiation: 12/23/2009","start_date":" 12/23/2009","primary_txt":" Primary completion: 01/15/2014","primary_completion_date":" 01/15/2014","study_txt":" Completion: 11/27/2015","study_completion_date":" 11/27/2015","last_update_posted":"2023-08-22"},{"id":"c1eaebee-1fe1-4b1d-ae34-797ecf1a4b25","acronym":"","url":"https://clinicaltrials.gov/study/NCT03755102","created_at":"2021-01-18T18:27:37.207Z","updated_at":"2024-07-02T16:35:43.343Z","phase":"Phase 1","brief_title":"A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.","source_id_and_acronym":"NCT03755102","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Vizimpro (dacomitinib)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 11/21/2018","start_date":" 11/21/2018","primary_txt":" Primary completion: 07/07/2023","primary_completion_date":" 07/07/2023","study_txt":" Completion: 07/07/2023","study_completion_date":" 07/07/2023","last_update_posted":"2023-07-12"},{"id":"f738c615-2ba4-4a90-91ed-b0dd6490fb34","acronym":"","url":"https://clinicaltrials.gov/study/NCT05271916","created_at":"2022-03-09T12:52:33.621Z","updated_at":"2024-07-02T16:35:50.146Z","phase":"Phase 1/2","brief_title":"First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations","source_id_and_acronym":"NCT05271916","lead_sponsor":"Shanghai Chest Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 10/13/2022","start_date":" 10/13/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2023-04-19"},{"id":"02bd8df0-2fe4-44b2-8867-3c5d0ec54fff","acronym":"","url":"https://clinicaltrials.gov/study/NCT03888092","created_at":"2021-01-18T19:09:24.084Z","updated_at":"2024-07-02T16:35:52.781Z","phase":"Phase 1/2","brief_title":"Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification","source_id_and_acronym":"NCT03888092","lead_sponsor":"Sunshine Lake Pharma Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR overexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e larotinib (Z650)"],"overall_status":"Completed","enrollment":" Enrollment 81","initiation":"Initiation: 08/18/2017","start_date":" 08/18/2017","primary_txt":" Primary completion: 12/13/2022","primary_completion_date":" 12/13/2022","study_txt":" Completion: 12/13/2022","study_completion_date":" 12/13/2022","last_update_posted":"2023-03-21"},{"id":"68799ef7-4ca6-42fa-afc7-d1b81bc51e00","acronym":"CAPLAND","url":"https://clinicaltrials.gov/study/NCT04811001","created_at":"2021-03-23T11:52:10.171Z","updated_at":"2024-07-02T16:35:55.090Z","phase":"Phase 2","brief_title":"Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations","source_id_and_acronym":"NCT04811001 - CAPLAND","lead_sponsor":"Fondazione Ricerca Traslazionale","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • ROS1","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • ALK rearrangement • EGFR L861Q • ALK mutation • ROS1 rearrangement • MET mutation • EGFR S768I • EGFR G719A • EGFR G719S • EGFR G719C","tags":["EGFR • HER-2 • BRAF • ALK • MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • ALK rearrangement • EGFR L861Q • ALK mutation • ROS1 rearrangement • MET mutation • EGFR S768I • EGFR G719A • EGFR G719S • EGFR G719C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 06/12/2020","start_date":" 06/12/2020","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-02-21"},{"id":"9653dfea-b314-42ba-85bf-254d9e1c24d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04415853","created_at":"2021-01-18T21:17:00.808Z","updated_at":"2024-07-02T16:36:05.477Z","phase":"Phase 3","brief_title":"Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer","source_id_and_acronym":"NCT04415853","lead_sponsor":"Sunshine Lake Pharma Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression • EGFR overexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • EGFR overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • Teysuno (gimeracil/oteracil/tegafur) • larotinib (Z650)"],"overall_status":"Recruiting","enrollment":" Enrollment 416","initiation":"Initiation: 01/21/2021","start_date":" 01/21/2021","primary_txt":" Primary completion: 08/01/2023","primary_completion_date":" 08/01/2023","study_txt":" Completion: 11/01/2023","study_completion_date":" 11/01/2023","last_update_posted":"2022-08-15"},{"id":"5bcd4523-c620-4633-8ed9-45f1a8034f09","acronym":"","url":"https://clinicaltrials.gov/study/NCT04675008","created_at":"2021-01-19T20:45:36.357Z","updated_at":"2024-07-02T16:36:36.615Z","phase":"Phase 2","brief_title":"Central Nervous System(CNS) Efficacy of Dacomitinib","source_id_and_acronym":"NCT04675008","lead_sponsor":"Samsung Medical Center","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/07/2020","start_date":" 12/07/2020","primary_txt":" Primary completion: 09/01/2022","primary_completion_date":" 09/01/2022","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2021-01-05"},{"id":"63192aae-11a2-4f2a-8e75-d623a9a7e540","acronym":"","url":"https://clinicaltrials.gov/study/NCT00553254","created_at":"2021-01-18T02:00:56.086Z","updated_at":"2024-07-02T16:36:39.987Z","phase":"Phase 2","brief_title":"Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer","source_id_and_acronym":"NCT00553254","lead_sponsor":"Pfizer","biomarkers":" HER-2 • KRAS","pipe":" | ","alterations":" EGFR mutation • HER-2 mutation • KRAS wild-type","tags":["HER-2 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 mutation • KRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • gefitinib • Vizimpro (dacomitinib)"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 02/05/2008","start_date":" 02/05/2008","primary_txt":" Primary completion: 08/03/2010","primary_completion_date":" 08/03/2010","study_txt":" Completion: 07/17/2014","study_completion_date":" 07/17/2014","last_update_posted":"2020-10-19"},{"id":"d0b42e8d-0ff1-441e-9a63-e9e3c47d4898","acronym":"","url":"https://clinicaltrials.gov/study/NCT00548093","created_at":"2021-01-18T01:59:42.670Z","updated_at":"2024-07-02T16:36:59.415Z","phase":"Phase 2","brief_title":"PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib","source_id_and_acronym":"NCT00548093","lead_sponsor":"Pfizer","biomarkers":" EGFR • HER-2 • KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["EGFR • HER-2 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • Vizimpro (dacomitinib)"],"overall_status":"Completed","enrollment":" Enrollment 66","initiation":"Initiation: 04/29/2008","start_date":" 04/29/2008","primary_txt":" Primary completion: 03/16/2010","primary_completion_date":" 03/16/2010","study_txt":" Completion: 06/11/2012","study_completion_date":" 06/11/2012","last_update_posted":"2019-05-21"},{"id":"75440a36-1244-4e48-815f-d9acda59e536","acronym":"ARCHER 1042","url":"https://clinicaltrials.gov/study/NCT01465802","created_at":"2021-01-18T06:06:02.965Z","updated_at":"2024-07-02T16:37:04.090Z","phase":"Phase 2","brief_title":"Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO","source_id_and_acronym":"NCT01465802 - ARCHER 1042","lead_sponsor":"Pfizer","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification • HER-2 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vizimpro (dacomitinib)"],"overall_status":"Completed","enrollment":" Enrollment 236","initiation":"Initiation: 12/26/2011","start_date":" 12/26/2011","primary_txt":" Primary completion: 05/18/2015","primary_completion_date":" 05/18/2015","study_txt":" Completion: 05/18/2015","study_completion_date":" 05/18/2015","last_update_posted":"2019-01-09"},{"id":"1fb44b58-1801-43d8-8a92-7003bfd70fec","acronym":"","url":"https://clinicaltrials.gov/study/NCT00818441","created_at":"2021-01-17T17:44:12.129Z","updated_at":"2024-07-02T16:37:04.106Z","phase":"Phase 2","brief_title":"Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung","source_id_and_acronym":"NCT00818441","lead_sponsor":"Pfizer","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • HER-2 amplification","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vizimpro (dacomitinib)"],"overall_status":"Completed","enrollment":" Enrollment 119","initiation":"Initiation: 03/11/2009","start_date":" 03/11/2009","primary_txt":" Primary completion: 04/27/2012","primary_completion_date":" 04/27/2012","study_txt":" Completion: 04/30/2015","study_completion_date":" 04/30/2015","last_update_posted":"2019-01-08"},{"id":"e1bf3faa-d8a3-4dd4-b0b8-8f5accb5cfa1","acronym":"M13DAP","url":"https://clinicaltrials.gov/study/NCT02039336","created_at":"2021-01-18T09:21:38.832Z","updated_at":"2025-02-25T15:33:00.773Z","phase":"Phase 1/2","brief_title":"Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC","source_id_and_acronym":"NCT02039336 - M13DAP","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS exon 2 mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS exon 2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Vizimpro (dacomitinib) • Gomekli (mirdametinib)"],"overall_status":"Unknown status","enrollment":" Enrollment 35","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2018-08-27"},{"id":"96da3c04-6ae0-4c04-b4a1-3d82a7bd3697","acronym":"","url":"https://clinicaltrials.gov/study/NCT01112527","created_at":"2021-01-18T04:24:27.723Z","updated_at":"2024-07-02T16:37:07.841Z","phase":"Phase 2","brief_title":"PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma","source_id_and_acronym":"NCT01112527","lead_sponsor":"Massachusetts General Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vizimpro (dacomitinib)"],"overall_status":"Completed","enrollment":" Enrollment 58","initiation":"Initiation: 04/01/2010","start_date":" 04/01/2010","primary_txt":" Primary completion: 09/01/2015","primary_completion_date":" 09/01/2015","study_txt":" Completion: 09/01/2015","study_completion_date":" 09/01/2015","last_update_posted":"2018-08-16"},{"id":"0e89afad-ced4-4e61-868a-54763247b904","acronym":"ARCHER 1009","url":"https://clinicaltrials.gov/study/NCT01360554","created_at":"2021-01-18T05:33:59.784Z","updated_at":"2024-07-02T16:37:21.808Z","phase":"Phase 3","brief_title":"ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT01360554 - ARCHER 1009","lead_sponsor":"Pfizer","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • Vizimpro (dacomitinib)"],"overall_status":"Completed","enrollment":" Enrollment 878","initiation":"Initiation: 06/16/2011","start_date":" 06/16/2011","primary_txt":" Primary completion: 09/30/2013","primary_completion_date":" 09/30/2013","study_txt":" Completion: 09/14/2015","study_completion_date":" 09/14/2015","last_update_posted":"2017-05-24"}]